To the top

Page Manager: Webmaster
Last update: 9/11/2012 3:13 PM

Tell a friend about this page
Print version

Clinical, genetic and exp… - University of Gothenburg, Sweden Till startsida
To content Read more about how we use cookies on

Clinical, genetic and experimental studies of the Brooke-Spiegler (CYLD) skin tumor syndrome

Journal article
Authors Mattias K Andersson
Lars Kölby
Jonas A Nilsson
Göran Stenman
Published in Journal of Plastic Surgery and Hand Surgery
Volume 53
Issue 2
Pages 71-75
ISSN 2000-656X
Publication year 2019
Published at Institute of Clinical Sciences, Department of Surgery
Sahlgrenska Cancer Center
Department of Laboratory Medicine
Institute of Clinical Sciences, Department of Plastic Surgery
Pages 71-75
Language en
Keywords Tumor, syndrome, craniofacial, proliferation, variants, Orthopedics, Surgery
Subject categories Cancer and Oncology, Plastic surgery


Brooke-Spiegler syndrome (BSS; a.k.a. tuban tumor syndrome) is an autosomal dominant inherited skin disorder caused by germline mutations in the CYLD tumor suppressor gene. BSS is characterized by multiple skin adnexal tumors, mainly cylindromas and spiradenomas on the head and neck. The tumors are often severely disfiguring and require repeated surgical interventions. Here, we describe a four-generation BSS-family with a novel germline c.1613_1614delGC CYLD mutation that introduces a premature STOP codon predicted to result in a truncated, inactivated CYLD protein. In addition, we present a pilot study describing establishment of the first patient-derived xenografts (PDXs) from cutaneous CYLD-defective cylindromas. Fresh tumor tissues from cylindromas were transplanted into immunocompromised mice to generate PDXs. One xenograft showed progressive tumor growth after 3 months whereas the others remained unchanged in size during the 6 months study period. Histopathological and immunohistochemical analyses of the PDXs revealed that they recapitulate the histological and molecular features of their respective primary tumors, including expression of NTRK3 and the oncogenic driver MYB. In summary, we present the first preclinical BSS-model that morphologically and genetically recapitulates human CYLD-defective cylindromas. This model will be useful for preclinical therapeutic drug testing and for further studies of the molecular pathogenesis of inherited cylindromas.

Page Manager: Webmaster|Last update: 9/11/2012

The University of Gothenburg uses cookies to provide you with the best possible user experience. By continuing on this website, you approve of our use of cookies.  What are cookies?